Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977961 | 0.90 | PTGER1 (0.40) | KMT2ASMN1; SMN2MEN1GPR132SMPD1 | |
| SCHEMBL2977441 | 0.88 | ACP1 (0.42) | MRGPRX4KMT2ASMN1; SMN2MEN1GPR132 | |
| SCHEMBL13220749 | 0.84 | TP53 (0.39) | KMT2ASMN1; SMN2 | |
| SCHEMBL13199240 | 0.82 | GAA (0.44) | MRGPRX4KMT2ASMN1; SMN2MEN1SMPD1 | |
| SCHEMBL2956660 | 0.77 | MAPT (0.51) | MRGPRX4KMT2ASMN1; SMN2MEN1SMPD1 | |
| SCHEMBL1842000 | 0.74 | MEN1 (0.56) | MRGPRX4KMT2AMEN1FFAR1MAOB | |
| SCHEMBL1839731 | 0.74 | CYP3A4 (0.42) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8233664 | 0.74 | MET (0.38) | KMT2ASMN1; SMN2 | |
| SCHEMBL2951993 | 0.73 | SMPD1 (0.44) | KMT2AMEN1SMPD1 | |
| SCHEMBL26455213 | 0.73 | MAOB (0.54) | MRGPRX4KMT2ASMN1; SMN2MEN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776920-B2 | Mandelic hydrazides | MERCK PATENT GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776920-B2 | Mandelic hydrazides | MERCK PATENT GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090221712-A1 | MANDELIC HYDRAZIDES | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221712-A1 | MANDELIC HYDRAZIDES | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221712-A1 | MANDELIC HYDRAZIDES | HK1, GLS, AGK | MRGPRX4 397/4885KMT2A 1864/4885SMN1; SMN2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.